Study of CC-99282 plus rituximab after CAR-T for lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a type of B-cell non-Hodgkin's lymphoma (such as large B-cell or follicular lymphoma).
- You have already received standard CAR-T cell therapy (like axi-cel, tisa-cel, or liso-cel) for your lymphoma.
- A PET/CT scan done 25 to 100 days after CAR-T shows some improvement, but also signs that the response was not complete (Deauville score of 3 or higher).
- Your blood counts (neutrophils, hemoglobin, platelets) and kidney and liver function meet certain minimum levels within the past month.
- You can swallow capsules and are willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This study tests a new way to prepare for CAR-T cell therapy for people with aggressive B-cell lymphoma who cannot have a stem cell transplant. Instead of using strong chemotherapy before CAR-T, this trial uses a pill-based regimen to keep the cancer under control and help the CAR-T cells work better.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Hear when a new B-Cell Non-Hodgkin Lymphoma-Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.